Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 165

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 165
---
 embryonal tumors that start in the cerebellum. They are invasive and, unlike most brain tumors, spread through the cerebrospinal
fluid, or CSF, and frequently metastasize to different locations in the brain and spinal cord. Treatments include resection, radiation
and chemotherapy. Approximately 350 patients are diagnosed with medulloblastoma per annum and 3,800 people are living with the disease
in the United States. The cumulative survival rate is approximately 60%, 52%, and 47% at 5 years, 10 years, and 20 years, respectively;
however, recurrence is nearly always fatal with no established standard of care.

| 83 |

The
University of Texas is undertaking a Phase 1 exploratory study in recurrent medulloblastoma patients using direct administration of MTX110
into the fourth ventricle, enabling it to circulate throughout the CSF.

In
2020, our non-exclusive worldwide, sublicensable license to certain patents of panobinostat was terminated by Secura Bio. We view MTX110
as an important asset and currently have two ongoing clinical trials for MTX110 and intend to commence two further clinical trials as
part of our MTX110 clinical program. We continue to enjoy freedom to use panobinostat for research purposes and we plan to continue to
pursue development of MTX110. We believe that the relevant Secura Bio patents may delay a launch of MTX110 for use in patients with DMG
should the product receive accelerated approval, however we do not anticipate it would have any impact on launching MTX110 for use in
patients with GBM. If we are unable to launch a product candidate until the patent expires, there could be a material adverse effect on
our business, financial condition and results of operations.

For
additional information regarding MTX110, see “—Recent Developments—MTX110 Developments.”

Commercial Agreements, Strategic Partnerships and Collaborations

We are currently collaborating
with biopharmaceutical companies, contract research organizations and universities on several of our development programs.

eRapa License.On April 25, 2024, we entered into the Emtora License Agreement with Emtora, relating to the license of eRapa, an oral product formulation of rapamycin (sirolimus), for use in the prevention, treatment, diagnosis, detection, monitoring and/or predisposition testing of all diseases, states or conditions in humans